Asset Details
Do you wish to reserve the book?
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
Do you wish to request the book?
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
2002
Overview
The vast majority of the world population is infected with at least one member of the human herpesvirus family. Herpes simplex virus (HSV) infections are the cause of cold sores and genital herpes as well as life-threatening or sight-impairing disease mainly in immunocompromized patients, pregnant women and newborns. Since the milestone development in the late 1970s of acyclovir (Zovirax), a nucleosidic inhibitor of the herpes DNA polymerase, no new non-nucleosidic anti-herpes drugs have been introduced. Here we report new inhibitors of the HSV helicase-primase with potent
in vitro
anti-herpes activity, a novel mechanism of action, a low resistance rate and superior efficacy against HSV in animal models. BAY 57-1293 (N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4- (2-pyridinyl)phenyl]acetamide), a well-tolerated member of this class of compounds, significantly reduces time to healing, prevents rebound of disease after cessation of treatment and, most importantly, reduces frequency and severity of recurrent disease. Thus, this class of drugs has significant potential for the treatment of HSV disease in humans, including those resistant to current medications.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Animals
/ Antiviral Agents - chemistry
/ Antiviral Agents - pharmacokinetics
/ Antiviral Agents - therapeutic use
/ Biomedical and Life Sciences
/ DNA
/ DNA Helicases - antagonists & inhibitors
/ Drug Evaluation, Preclinical
/ Enzyme Inhibitors - chemistry
/ Enzyme Inhibitors - pharmacokinetics
/ Enzyme Inhibitors - therapeutic use
/ Female
/ Herpes Simplex - drug therapy
/ Humans
/ Kinases
/ Mice
/ Pyridines - pharmacokinetics
/ Safety
